Effect of Food on the Pharmacokinetics, Pharmacodynamics, and Safety of Zastaprazan, a Potassium‐Competitive Acid Blocker, in Healthy Participants
Clinical and Translational Science · 2026-11 · 19 (11)
DOI: 10.1111/cts.70757 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Translational Science, online erschienen am 30.10.2026. Verfasst von Hyoeun Lee und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology and Therapeutics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Food-Drug Interactions. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Zastaprazan (JP‐1366) is a novel potassium‐competitive acid blocker characterized by rapid onset and sustained acid suppression. This study aimed to evaluate the effect of food on the pharmacokinetics (PK), pharmacodynamics (PD), and safety of zastaprazan in healthy participants. In this randomized, open‐label, two‐period crossover phase 1 study, 24 healthy participants received a single oral dose of zastaprazan 20 mg under fasted and fed conditions. PK parameters were evaluated using noncompartmental analysis, and PD effects were assessed through continuous intragastric pH monitoring. Under fed conditions, peak exposure (Cmax) decreased (geometric mean ratio [GMR], 0.6997; 90% confidence interval [CI], 0.6292–0.7781), whereas systemic exposure (AUC last ) increased (GMR, 1.3783; 90% CI, 1.2688–1.4973), accompanied by a delayed T max . Despite these PK differences, PD outcomes were comparable between fed and fasted conditions. The percentage of time with intragastric pH ≥ 4 over 24 h was similar under fed and fasted conditions (70.01% vs. 69.19%), with no meaningful differences observed in other pH‐based parameters. Zastaprazan was well tolerated, and no clinically significant safety concerns were identified. Food altered the rate and extent of zastaprazan absorption but did not affect its PD response. These findings indicate that food‐related PK changes do not meaningfully affect PD outcomes and support the administration of zastaprazan without regard to meals. This flexibility may enhance its clinical utility as an acid‐suppressive therapy. Trial Registration: The study was registered at ClinicalTrials.gov (NCT05712681)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology and Therapeutics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
- Department of Pediatric Surgery, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Republic of Korea.
- Onconic Therapeutics, Seoul, Korea.
ORCID-Profile: Hyoeun Lee, Soo-Min Jung, Shi-Hyang Lee, Eun Na Kim, Kyun-Seop Bae, Hyeong-Seok Lim
Zitieren
APA
Lee, H., Yoon, S. K., Jung, S. M., Lee, M. H., Lee, S. H., Kim, E. N., Kim, J., Cha, H., Bae, K. S., & Lim, H. S. (2026). Effect of Food on the Pharmacokinetics, Pharmacodynamics, and Safety of Zastaprazan, a Potassium‐Competitive Acid Blocker, in Healthy Participants. Clinical and Translational Science, 19(11). https://doi.org/10.1111/cts.70757
Vancouver
Lee H, Yoon SK, Jung SM, Lee MH, Lee SH, Kim EN, et al. Effect of Food on the Pharmacokinetics, Pharmacodynamics, and Safety of Zastaprazan, a Potassium‐Competitive Acid Blocker, in Healthy Participants. Clinical and Translational Science. 2026;19(11). doi:10.1111/cts.70757
BibTeX
@article{Lee2026,
author = {Lee, Hyoeun and Yoon, Seok-Kyu and Jung, Soo-Min and Lee, Moon Hee and Lee, Shi-Hyang and Kim, Eun Na and Kim, John and Cha, Hyunju and Bae, Kyun-Seop and Lim, Hyeong-Seok},
title = {Effect of Food on the Pharmacokinetics, Pharmacodynamics, and Safety of Zastaprazan, a Potassium‐Competitive Acid Blocker, in Healthy Participants},
journal = {Clinical and Translational Science},
year = {2026},
volume = {19},
number = {11},
doi = {10.1111/cts.70757}
}
EUVIMED